Use of FK506 Immunosuppressive Therapy in Pancreas Transplantation

Abstract

The purpose of this study was to evaluate the safety, efficacy, and transplant outcomes associated with FK506 rescue and maintenance therapy in pancreas transplant recipients. A chart review was conducted on 10 patients receiving FK506 after pancreas transplantation. Transplant outcomes were compared with an equivalent group of patients receiving cyclosporine. Medication dose, side effects, infections, rejection episodes, glycemic control, and graft survival were recorded from 2 to 28 weeks after transplant. Rescue therapy was successful in the patients who were converted to FK506 prior to a significant decline in glycemic control, whereas those patients who were converted after a decline in glycemic control were required to return to exogenous insulin administration. Neurological complications, nephrotoxicity, incidence of infection, hypertension, rejection, and graft survival were similar for both groups. Use of FK506 is comparable to cyclosporine in pancreas allograft recipients and successful conversion from cyclosporine to FK506 can be undertaken for rescue therapy.

Get full access to this article

View all access options for this article.

References

Moudry-Munns

Greussner

Sutherland

DER

. Analysis of United States Pancreas Transplant Registry data. J Transplant Coordination. 1994;4:18–22.

Kahan

Ghobrial

. Immunosuppressive agents. Surg Clin North Am. 1994;74(5):1029–1054.

Gruessner

Moudry-Munns

. Influence of multiple factors (age, transplant number, recipient category, donor source) on outcomes of pancreas transplantation at one institution. Transplant Proc. 1993;25:1303–1305.

Goto

Kino

Hatanaka

. Discovery of FK-506, a novel immunosuppressant isolated from Streptomyces tsukubaensis. Transplant Proc. 1987;19(suppl 6):4–8.

Goto

Kino

Hatanaka

. FK506: Historical perspectives. Transplant Proc. 1991;23:2713–2717.

Schreier

Baumann

Jenke

. Inhibition of T-cell signaling pathways by immunophilin drug complexes: Are side effects inherent to immunosuppressive properties? Transplant Proc. 1993;25:502–507.

Kay

Moore

Doe

SEA

. The mechanism of action of FK506. Transplant Proc. 1990;22(suppl 1):96–99.

Bishop

. Cyclosporin A and FK506 mediate differential effects on T-cell activation in viva. J Immunol. 1992;148:1049–1045.

Klintmalm

. A review of FK506: A new immunosuppressant agent for the prevention and rescue of graft rejection. Transplantation Rev. 1994;8(2):53–63.

10.

United States FK506 Multicenter Liver Study Group. A comparison of tacrolimus (FK506) and cyclosporine A for immunosuppression in liver transplantation. N Engl J Med. 1994;331(17):1110–1115.

11.

United States FK506 Multicenter Liver Study Group. Use of FK506 for the prevention of recurrent allograft rejection after successful conversion from cyclosporine A for refractory rejection. Transplant Proc. 1993;25(1):635–637.

12.

Jordan

Shapiro

Vivas

. FK506 salvage of renal allografts with ongoing rejection failing cyclosporine A immunosuppression. Transplant Proc. 1993;25(1):638–640.

13.

European FK506 Multicenter Liver Study Group. Randomized trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection. Lancet. 1994;344(8920):423–428.